Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

Abstract

Patients with systolic HF of ischaemic aetiology who have galectin-3 values <19.0 ng/mL may benefit from rosuvastatin treatment. However, the data from this post hoc analysis should be interpreted with caution since the overall results of the CORONA study did not show a significant effect on the primary endpoint.

Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience

“…Recent studies have revealed that Gal-3 appears to be a promising prognostic biomarker in HF patients [3,6,7,21,23,24]. In our study, patients who died during the follow-up period presented significantly higher baseline Gal-3 levels than the survivors, which is in line with some previous reports [3,6,7,21,23,24].…”

“…In our study, patients who died during the follow-up period presented significantly higher baseline Gal-3 levels than the survivors, which is in line with some previous reports [3,6,7,21,23,24]. Nevertheless, the clinical utility of this particle in the diagnostics as well as monitoring of therapy still needs to be addressed in large, prospective trials.…”

Efekty leczenia atorwastatyną chorych w średnim wieku z zaawansowaną kardiomiopatią rozstrzeniową — prospektywne randomizowane badanie jednoośrodkowe

“…Predictors of a good response to statin therapy were also looked for in the study by Gullestad et al [32] who evaluated the efficacy of statin treatment in patients with chronic ischemic heart failure in relation to plasma galectin-3 level, a marker of myocardial fibrosis. This analysis included 1492 participants of the CORONA study who were randomized to rosuvastatin 10 mg daily or placebo.…”

Galectin 3: Newest Marker of HF Outcomes

“…Among patients with galectin-3 levels less than or equal to the median value of 19.0 ng/ml, those treated with rosuvastatin had a 30.4 % reduction in CV death, non-fatal MI, and non-fatal stroke when compared to those who received placebo (p = 0.036). Conversely, patients with levels above the median derived no benefit from the drug [30]. In a substudy of the Val-HeFT trial, galectin-3 similarly predicted whether HF patients benefited from treatment with the ARB valsartan.…”